Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Apyx Medical (APYX) Shares Outstanding (2016 - 2026)

Apyx Medical filings provide 16 years of Shares Outstanding readings, the most recent being $41.8 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 10.56% to $41.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.8 million, a 10.56% increase, with the full-year FY2025 number at $41.8 million, up 10.56% from a year prior.
  • Shares Outstanding hit $41.8 million in Q4 2025 for Apyx Medical, up from $37.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $41.8 million in Q4 2025 to a low of $34.3 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $34.6 million (2023), compared with a mean of $35.5 million.
  • Biggest five-year swings in Shares Outstanding: changed 0.0% in 2024 and later rose 10.56% in 2025.
  • Apyx Medical's Shares Outstanding stood at $34.4 million in 2021, then increased by 0.55% to $34.6 million in 2022, then grew by 0.13% to $34.6 million in 2023, then rose by 9.09% to $37.8 million in 2024, then rose by 10.56% to $41.8 million in 2025.
  • The last three reported values for Shares Outstanding were $41.8 million (Q4 2025), $37.8 million (Q3 2025), and $37.8 million (Q2 2025) per Business Quant data.